[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639812":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":27,"responsibleParty":159,"collaborators":10,"id":161,"slug":162,"hasResults":163,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":163,"sex":169,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":10,"studyType":175,"phases":10,"briefSummary":176,"conditions":177,"keywords":10,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"aHCC\u002FuHCC",null,"patients with advanced or unresectable HCC (uHCC) treated with STRIDE in Italy according to routine clinical practice.",[13],"Drug: STRIDE",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","STRIDE","Tremelimumab 300 mg as a single dose administered in combination with durvalumab 1500 mg at Cycle 1\u002FDay 1, followed by durvalumab monotherapy every 4 weeks.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"AstraZeneca Clinical Study Information Center AstraZeneca Clinical Study Information Center","CONTACT","+1877240","9479","information.center@astrazeneca.com",[28,41,49,58,66,74,79,87,95,103,111,119,127,135,143,151],{"facility":29,"status":30,"city":31,"state":10,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":10},"Research site","ACTIVE_NOT_RECRUITING","Ancona","60126","Italy","IT",{"type":36,"coordinates":37},"Point",[38,39],13.5103,43.60717,{"lat":39,"lon":38},{"facility":29,"status":30,"city":42,"state":10,"zip":43,"country":33,"countryCode":34,"cosmosGeoPoint":44,"geoPoint":48,"contacts":10},"Bergamo","24129",{"type":36,"coordinates":45},[46,47],9.66721,45.69601,{"lat":47,"lon":46},{"facility":29,"status":50,"city":51,"state":10,"zip":52,"country":33,"countryCode":34,"cosmosGeoPoint":53,"geoPoint":57,"contacts":10},"RECRUITING","Foggia","71122",{"type":36,"coordinates":54},[55,56],15.55188,41.45845,{"lat":56,"lon":55},{"facility":29,"status":30,"city":59,"state":10,"zip":60,"country":33,"countryCode":34,"cosmosGeoPoint":61,"geoPoint":65,"contacts":10},"Meldola","47014",{"type":36,"coordinates":62},[63,64],12.0626,44.12775,{"lat":64,"lon":63},{"facility":29,"status":30,"city":67,"state":10,"zip":68,"country":33,"countryCode":34,"cosmosGeoPoint":69,"geoPoint":73,"contacts":10},"Milan","20122",{"type":36,"coordinates":70},[71,72],12.59836,42.78235,{"lat":72,"lon":71},{"facility":29,"status":30,"city":67,"state":10,"zip":75,"country":33,"countryCode":34,"cosmosGeoPoint":76,"geoPoint":78,"contacts":10},"20162",{"type":36,"coordinates":77},[71,72],{"lat":72,"lon":71},{"facility":29,"status":30,"city":80,"state":10,"zip":81,"country":33,"countryCode":34,"cosmosGeoPoint":82,"geoPoint":86,"contacts":10},"Modena","41124",{"type":36,"coordinates":83},[84,85],10.92539,44.64783,{"lat":85,"lon":84},{"facility":29,"status":50,"city":88,"state":10,"zip":89,"country":33,"countryCode":34,"cosmosGeoPoint":90,"geoPoint":94,"contacts":10},"Naples","80131",{"type":36,"coordinates":91},[92,93],14.26811,40.85216,{"lat":93,"lon":92},{"facility":29,"status":30,"city":96,"state":10,"zip":97,"country":33,"countryCode":34,"cosmosGeoPoint":98,"geoPoint":102,"contacts":10},"Padova","35100",{"type":36,"coordinates":99},[100,101],11.14261,44.38225,{"lat":101,"lon":100},{"facility":29,"status":30,"city":104,"state":10,"zip":105,"country":33,"countryCode":34,"cosmosGeoPoint":106,"geoPoint":110,"contacts":10},"Palermo","90127",{"type":36,"coordinates":107},[108,109],13.3636,38.1166,{"lat":109,"lon":108},{"facility":29,"status":30,"city":112,"state":10,"zip":113,"country":33,"countryCode":34,"cosmosGeoPoint":114,"geoPoint":118,"contacts":10},"Pisa","56126",{"type":36,"coordinates":115},[116,117],10.4036,43.70853,{"lat":117,"lon":116},{"facility":29,"status":30,"city":120,"state":10,"zip":121,"country":33,"countryCode":34,"cosmosGeoPoint":122,"geoPoint":126,"contacts":10},"Pozzuoli","80078",{"type":36,"coordinates":123},[124,125],14.0952,40.84394,{"lat":125,"lon":124},{"facility":29,"status":30,"city":128,"state":10,"zip":129,"country":33,"countryCode":34,"cosmosGeoPoint":130,"geoPoint":134,"contacts":10},"Roma","00168",{"type":36,"coordinates":131},[132,133],11.10642,44.99364,{"lat":133,"lon":132},{"facility":29,"status":30,"city":136,"state":10,"zip":137,"country":33,"countryCode":34,"cosmosGeoPoint":138,"geoPoint":142,"contacts":10},"Rozzano","20089",{"type":36,"coordinates":139},[140,141],9.1559,45.38193,{"lat":141,"lon":140},{"facility":29,"status":30,"city":144,"state":10,"zip":145,"country":33,"countryCode":34,"cosmosGeoPoint":146,"geoPoint":150,"contacts":10},"Torino","10126",{"type":36,"coordinates":147},[148,149],11.99138,44.88856,{"lat":149,"lon":148},{"facility":29,"status":30,"city":152,"state":10,"zip":153,"country":33,"countryCode":34,"cosmosGeoPoint":154,"geoPoint":158,"contacts":10},"Verona","37134",{"type":36,"coordinates":155},[156,157],10.9938,45.43854,{"lat":157,"lon":156},{"type":160,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100639812","monterosa---italian-multicenter-observational-study-to-evaluate-time-to-clinical-hepatic-decompensation-quality-of-life-effectiveness-and-safety-of-tremelimumab-plus-durvalumab-in-patients-with-advanced-or-unresectable-hepatocellular-carcinoma-who-have-received-no-prior-systemic-treatment-100639812",false,"NCT07607769","MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.","MONTEROSA Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment. (Real World Observational Study of STRIDE Regimen for Advanced HCC)","MONTEROSA","Inclusion Criteria:\n\n* \\- Signed informed consent.\n* Age ≥ 18 years.\n* Histologically or radiologically confirmed diagnosis of advanced or unresectable HCC.\n* BCLC B or C HCC.\n* Child-Pugh A (score 5 or 6).\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score 0 or 1.\n* Planned first-line treatment of advanced\u002FuHCC with STRIDE.\n\nExclusion Criteria:\n\n* \\- Any previous line of systemic therapy for HCC.\n* Any prior or concomitant immunotherapy.\n* Prior allogeneic organ or bone marrow transplant.\n* Documented active or previous GI bleeding within the previous 12 months.\n* Main trunk portal vein thrombosis.\n* Autoimmune disease requiring treatment with immunosuppressive medication.\n* Known hypersensitivity to the active substance or to any of the STRIDE excipients.\n* Pregnancy or breastfeeding","ALL","18 Years","100 Years",{"count":173,"type":174},200,"ESTIMATED","OBSERVATIONAL","Italian multicenter observational study to evaluate time to clinical hepatic decompensation, quality of life, effectiveness, and safety of tremelimumab plus durvalumab in patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic treatment.",[178],"Hepatocellular Carcinoma","2026-06-19",{"date":181,"type":182},"2026-06-23","ACTUAL",{"date":184,"type":182},"2026-04-16",{"date":186,"type":174},"2028-10-31",{"name":5,"class":6},16]